Embecta Corp. (NASDAQ:EMBC – Get Free Report) has received an average rating of “Reduce” from the five brokerages that are covering the firm, MarketBeat.com reports. One analyst has rated the stock with a sell recommendation and four have assigned a hold recommendation to the company. The average twelve-month price target among brokers that have covered the stock in the last year is $11.00.
Separately, Weiss Ratings upgraded shares of Embecta from a “sell (d+)” rating to a “hold (c-)” rating in a report on Monday, November 2nd.
Get Our Latest Stock Analysis on EMBC
Embecta Price Performance
Shares of NASDAQ EMBC opened at $6.46 on Monday. The stock has a market cap of $366.02 million, a P/E ratio of 4.36 and a beta of 0.81. The firm’s 50-day simple moving average is $5.97 and its 200 day simple moving average is $6.19. Embecta has a fifty-two week low of $2.77 and a fifty-two week high of $14.81.
Insider Buying and Selling
In other news, Director Milton Mayo Morris sold 6,293 shares of Embecta stock in a transaction on Friday, September 4th. The stock was sold at an average price of $5.88, for a total transaction of $37,002.84. Following the transaction, the director directly owned 53,828 shares in the company, valued at approximately $316,508.64. This trade represents a 10.47% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. 1.30% of the stock is currently owned by insiders.
Institutional Inflows and Outflows
Large investors have recently bought and sold shares of the company. Walleye Capital LLC purchased a new position in Embecta in the 1st quarter worth about $7,013,000. Krensavage Asset Management LLC increased its position in shares of Embecta by 54.4% in the second quarter. Krensavage Asset Management LLC now owns 1,135,340 shares of the company’s stock worth $3,701,000 after acquiring an additional 400,000 shares in the last quarter. Chicago Partners Investment Group LLC purchased a new position in shares of Embecta in the third quarter worth approximately $1,813,000. Hsbc Holdings PLC raised its holdings in shares of Embecta by 1,268.6% during the first quarter. Hsbc Holdings PLC now owns 212,491 shares of the company’s stock valued at $1,882,000 after acquiring an additional 196,965 shares during the period. Finally, CWA Asset Management Group LLC raised its holdings in shares of Embecta by 43.4% during the third quarter. CWA Asset Management Group LLC now owns 537,838 shares of the company’s stock valued at $3,044,000 after acquiring an additional 162,891 shares during the period. Institutional investors own 93.83% of the company’s stock.
About Embecta
Embecta is a medical device company focused on products for people who use insulin to manage diabetes. Its portfolio includes pen needles, insulin syringes and safety injection devices, serving both individuals and healthcare professionals. The company was formed in 2022 when Becton, Dickinson and Company (BD) separated its diabetes care business into an independent company. Embecta continues to build on that business’s history of developing injection devices for diabetes care. Embecta serves customers in markets around the world.
See Also
- Five stocks we like better than Embecta
- Intuitive Machines’ Business Is Taking Off—Will Its Stock Follow?
- The Next Big Thing May Not Be One Thing: Inside Lazard’s Megatrends ETF
- 3 Power and Grid Stocks That Could Keep Growing Even if AI Spending Slows
- Applied Materials Beats and Raises, But Investors Stay Unconvinced
Receive News & Ratings for Embecta Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Embecta and related companies with MarketBeat.com's FREE daily email newsletter.
